|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
decreases expression multiple interactions |
ISO |
Heme results in decreased expression of ALAS1 protein MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Heme binds to ALB protein abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:92,120,332...92,140,790
Ensembl chr 9:92,120,306...92,136,376
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:26,425,017...26,514,899
Ensembl chr 6:26,425,954...26,507,477
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,084,269...76,109,111
Ensembl chr 9:76,084,334...76,109,100
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:9,192,233...9,210,498
Ensembl chr 5:9,192,100...9,210,731
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:85,518,637...85,555,079
Ensembl chr10:85,518,621...85,555,575
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression multiple interactions |
ISO |
Heme results in increased expression of F3 mRNA Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA Heme results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637
|
|
G |
Gfod1 |
Gfo/Idh/MocA-like oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:105,236,795...105,337,226
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:130,469,840...130,479,802
Ensembl chr 5:130,469,840...130,478,561
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases degradation increases metabolic processing decreases expression decreases abundance increases expression |
ISO EXP |
[HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased metabolism of Heme Heme results in decreased expression of HMOX1 mRNA HMOX1 protein results in decreased abundance of Heme [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:42,380,981...42,384,625
Ensembl chr13:42,380,981...42,384,625
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:83,932,234...83,958,243
Ensembl chr13:83,948,124...83,958,227
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107
|
|
G |
Ly96 |
lymphocyte antigen 96 |
affects binding multiple interactions |
ISO |
Heme binds to LY96 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions increases secretion |
ISO |
SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK1 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36115635 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK3 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK8 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:85,727,989...85,731,523
Ensembl chr13:85,728,076...85,731,469
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Mt1 |
metallothionein 1 |
decreases response to substance multiple interactions |
ISO |
MT1A protein results in decreased susceptibility to Heme [Heme co-treated with HPX protein] affects the activity of MT1 promoter |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases localization |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:121,433,993...121,439,158
Ensembl chr 5:121,434,096...121,439,154
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:103,956,678...104,006,763
Ensembl chr 9:103,956,678...104,006,783
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:88,313,837...88,366,182
Ensembl chr10:88,314,651...88,362,412
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:183,544,487...183,552,928
Ensembl chr 2:183,544,499...183,552,785
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,406,172...135,419,332
Ensembl chr 5:135,406,176...135,419,235
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:71,310,387...71,396,752
Ensembl chr18:71,311,020...71,395,709
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization increases localization multiple interactions |
ISO |
Heme analog affects the localization of RELA protein Heme results in increased localization of RELA protein LY96 protein promotes the reaction [Heme results in increased localization of RELA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:130,026,255...130,031,127
Ensembl chr 7:130,026,341...130,030,248
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:106,746,642...106,768,182
Ensembl chr 3:106,656,742...106,768,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848
|
|
G |
Smarcb1 |
SWI/SNF related BAF chromatin remodeling complex subunit B1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:12,741,164...12,763,616
Ensembl chr20:12,741,477...12,763,620
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions affects binding |
ISO |
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] Heme binds to TLR4 protein |
CTD |
PMID:36115635 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 PMID:36115635 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:79,462,406...79,492,888
Ensembl chr16:79,462,402...79,492,693
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:56,286,604...56,345,160
Ensembl chr 5:56,286,725...56,345,513
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:79,185,563...79,191,657
Ensembl chr10:79,186,647...79,191,657
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:80,743,134...80,829,253
Ensembl chr11:80,743,134...80,829,208
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions decreases expression |
ISO |
MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:92,120,332...92,140,790
Ensembl chr 9:92,120,306...92,136,376
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:26,425,017...26,514,899
Ensembl chr 6:26,425,954...26,507,477
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,084,269...76,109,111
Ensembl chr 9:76,084,334...76,109,100
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:9,192,233...9,210,498
Ensembl chr 5:9,192,100...9,210,731
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:85,518,637...85,555,079
Ensembl chr10:85,518,621...85,555,575
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression multiple interactions |
EXP |
Heme results in increased expression of FABP2 mRNA [Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637
|
|
G |
Gfod1 |
Gfo/Idh/MocA-like oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:105,236,795...105,337,226
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:130,469,840...130,479,802
Ensembl chr 5:130,469,840...130,478,561
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions increases degradation decreases abundance increases metabolic processing increases expression |
ISO EXP |
Heme results in decreased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] HMOX1 protein results in increased degradation of Heme HMOX1 protein results in decreased abundance of Heme HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:42,380,981...42,384,625
Ensembl chr13:42,380,981...42,384,625
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:83,932,234...83,958,243
Ensembl chr13:83,948,124...83,958,227
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107
|
|
G |
Ly96 |
lymphocyte antigen 96 |
affects binding multiple interactions |
ISO |
Heme binds to LY96 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
Heme analog results in increased secretion of LYZ protein SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36115635 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK3 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:85,727,989...85,731,523
Ensembl chr13:85,728,076...85,731,469
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Mt1 |
metallothionein 1 |
decreases response to substance multiple interactions |
ISO |
MT1A protein results in decreased susceptibility to Heme [Heme co-treated with HPX protein] affects the activity of MT1 promoter |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases localization |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:121,433,993...121,439,158
Ensembl chr 5:121,434,096...121,439,154
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:103,956,678...104,006,763
Ensembl chr 9:103,956,678...104,006,783
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:88,313,837...88,366,182
Ensembl chr10:88,314,651...88,362,412
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:183,544,487...183,552,928
Ensembl chr 2:183,544,499...183,552,785
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,406,172...135,419,332
Ensembl chr 5:135,406,176...135,419,235
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:71,310,387...71,396,752
Ensembl chr18:71,311,020...71,395,709
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization multiple interactions increases localization |
ISO |
Heme analog affects the localization of RELA protein LY96 protein promotes the reaction [Heme results in increased localization of RELA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:130,026,255...130,031,127
Ensembl chr 7:130,026,341...130,030,248
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:106,746,642...106,768,182
Ensembl chr 3:106,656,742...106,768,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848
|
|
G |
Smarcb1 |
SWI/SNF related BAF chromatin remodeling complex subunit B1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:12,741,164...12,763,616
Ensembl chr20:12,741,477...12,763,620
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Tlr4 |
toll-like receptor 4 |
affects binding multiple interactions |
ISO |
Heme binds to TLR4 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 PMID:36115635 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:79,462,406...79,492,888
Ensembl chr16:79,462,402...79,492,693
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:56,286,604...56,345,160
Ensembl chr 5:56,286,725...56,345,513
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:79,185,563...79,191,657
Ensembl chr10:79,186,647...79,191,657
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:80,743,134...80,829,253
Ensembl chr11:80,743,134...80,829,208
|
|
|
G |
Aco1 |
aconitase 1 |
decreases activity |
EXP |
Hemin results in decreased activity of ACO1 protein |
CTD |
PMID:16568477 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Aco2 |
aconitase 2 |
increases expression |
EXP |
Hemin results in increased expression of ACO2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases secretion |
EXP |
Hemin results in increased secretion of ADIPOQ protein |
CTD |
PMID:20016031 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases degradation |
EXP |
Hemin results in increased degradation of ALAS1 protein |
CTD |
PMID:17761694 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of ALAS2 mRNA [catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol promotes the reaction [Hemin results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of ALAS2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of ALAS2 mRNA] |
CTD |
PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Hemin binds to ALB protein |
CTD |
PMID:10506189 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
EXP |
Hemin inhibits the reaction [Nitroglycerin results in decreased activity of ALDH2 protein] |
CTD |
PMID:17541025 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
increases expression |
ISO |
Hemin results in increased expression of ARL6IP5 protein |
CTD |
PMID:16430862 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions affects localization increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] affects the localization of BACH1 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of BACH1 protein; [Hemin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of BACH1 mRNA; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BACH1 protein]; Hemin results in decreased localization of and results in decreased activity of BACH1 protein Hemin affects the localization of BACH1 protein Hemin results in increased expression of BACH1 mRNA; Hemin results in increased expression of BACH1 protein |
CTD |
PMID:18550526 PMID:31518892 PMID:33434570 PMID:36096218 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Hemin promotes the reaction [Cisplatin results in increased expression of BAX protein] Hemin results in increased expression of BAX protein Hemin inhibits the reaction [lead acetate results in increased expression of BAX protein] |
CTD |
PMID:27815112 PMID:29797346 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Hemin results in decreased expression of BCL2 protein Hemin inhibits the reaction [lead acetate results in decreased expression of BCL2 protein] |
CTD |
PMID:27815112 PMID:29797346 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
Hemin results in increased expression of BIRC2 protein |
CTD |
PMID:14647439 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP ISO |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in increased cleavage of CASP3 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]] Hemin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein] Hemin results in increased cleavage of CASP3 protein [SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form |
CTD |
PMID:17173083 PMID:18845130 PMID:19150641 PMID:19520142 PMID:26747958 PMID:27815112 PMID:31054940 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein] Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Hemin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:19150641 PMID:27815112 PMID:35691465 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein] |
CTD |
PMID:35691465 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of CDH1 mRNA |
CTD |
PMID:29269057 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein] |
CTD |
PMID:14647439 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases degradation |
ISO |
Hemin results in decreased degradation of CDKN1B protein |
CTD |
PMID:17283133 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO |
HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA] |
CTD |
PMID:29749404 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein]; [Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [thiamet G results in increased O-linked glycosylation of CHD4 protein]; [Hemin co-treated with hexamethylene bisacetamide] results in decreased O-linked glycosylation of CHD4 protein |
CTD |
PMID:27231347 |
|
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crh |
corticotropin releasing hormone |
increases secretion multiple interactions |
ISO |
Hemin results in increased secretion of CRH protein mesoporphyrin IX analog inhibits the reaction [Hemin results in increased secretion of CRH protein] |
CTD |
PMID:11232018 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]; Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]] |
CTD |
PMID:23272707 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [Mercuric Chloride inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [sodium arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]] |
CTD |
PMID:20188822 PMID:20837117 PMID:22120038 PMID:22159698 PMID:26747958 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP1A2 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]] |
CTD |
PMID:22159698 PMID:26747958 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP2B1 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP2B1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP2B1 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]] |
CTD |
PMID:11368792 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] Hemin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein] Hemin results in increased expression of DDIT3 mRNA |
CTD |
PMID:26747958 PMID:29749404 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
ISO |
Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of DLG1 protein] |
CTD |
PMID:36096218 |
|
NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of EFNA1 mRNA |
CTD |
PMID:32198055 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [Hemin results in increased expression of FOS mRNA]; KN 62 inhibits the reaction [Hemin results in increased expression of FOS mRNA]; staurosporine aglycone inhibits the reaction [Hemin results in increased expression of FOS mRNA] |
CTD |
PMID:10381381 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
decreases expression |
ISO |
Hemin results in decreased expression of FOSL1 protein |
CTD |
PMID:20006635 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
EXP ISO |
Hemin results in increased expression of FTH1 mRNA; Hemin results in increased expression of FTH1 protein |
CTD |
PMID:15893546 PMID:16568477 PMID:17469137 PMID:29749404 PMID:31054940 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression |
ISO EXP |
[Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA Hemin results in increased expression of FTL mRNA; Hemin results in increased expression of FTL1 protein Hemin results in increased expression of FTL1 mRNA |
CTD |
PMID:12393473 PMID:15893546 PMID:16568477 PMID:29749404 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr17:4,482,168...4,485,153
|
|
G |
Gata1 |
GATA binding protein 1 |
increases expression multiple interactions affects expression decreases expression |
ISO |
Hemin results in increased expression of GATA1 mRNA catechol promotes the reaction [Hemin results in increased expression of GATA1 mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Hemin promotes the reaction [catechol results in increased expression of GATA1 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA] Hemin affects the expression of GATA1 mRNA Hemin results in decreased expression of GATA1 protein |
CTD |
PMID:21414390 PMID:23973255 PMID:28552822 PMID:37329354 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gata2 |
GATA binding protein 2 |
decreases expression multiple interactions affects expression |
ISO |
Hemin results in decreased expression of GATA2 mRNA; Hemin results in decreased expression of GATA2 protein hydroquinone affects the reaction [Hemin affects the expression of GATA2 mRNA]; hydroquinone inhibits the reaction [Hemin results in decreased expression of GATA2 protein]; hydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of GATA2 mRNA] |
CTD |
PMID:21414390 PMID:37329354 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GCLC mRNA; Hemin results in increased expression of GCLC protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC protein |
CTD |
PMID:16631525 PMID:33434570 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GCLM mRNA; Hemin results in increased expression of GCLM protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM protein |
CTD |
PMID:33434570 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR protein Hemin results in increased expression of GSR mRNA; Hemin results in increased expression of GSR protein |
CTD |
PMID:33434570 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GSTO1 mRNA [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSTO1 mRNA |
CTD |
PMID:33434570 |
|
NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Hemin results in increased stability of and results in increased expression of GSTP1 mRNA |
CTD |
PMID:15313425 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
decreases activity |
ISO |
Hemin results in decreased activity of GSTZ1 protein |
CTD |
PMID:1846734 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression decreases response to substance multiple interactions |
ISO |
Hemin results in increased expression of HAMP mRNA HAMP mRNA results in decreased susceptibility to Hemin [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA; [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA]; necrostatin-1 promotes the reaction [HAMP mRNA results in decreased susceptibility to Hemin] |
CTD |
PMID:29749404 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol promotes the reaction [Hemin results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HBB mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]; trichostatin A inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 PMID:30327826 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA Hemin results in decreased expression of HIF1A mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA |
CTD |
PMID:12393473 PMID:29749404 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol promotes the reaction [Hemin results in increased expression of HMBS mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HMBS mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases response to substance increases activity increases expression decreases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 protein; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased activity of HMOX1 protein] which results in decreased chemical synthesis of Reactive Oxygen Species; [Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Genistein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Curcumin results in increased expression of HMOX1 mRNA]; Hemin results in increased expression of and results in increased activity of HMOX1 protein; herbimycin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Hemin 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Hemin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [3-hydroxyflavone results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [baicalein results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; Hemin promotes the reaction [kaempferol results in increased expression of HMOX1 protein]; Hemin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Quercetin results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; [Hemin co-treated with Fructose] results in increased expression of HMOX1 protein; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 mRNA; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 protein; [Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein]; chromium mesoporphyrin inhibits the reaction [[Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] Hemin results in increased expression of HMOX1 mRNA; Hemin results in increased expression of HMOX1 protein |
CTD |
PMID:3343248 PMID:8764571 PMID:9337616 PMID:9722676 PMID:10349844 PMID:10473555 PMID:11232018 PMID:12051994 PMID:12393473 PMID:12690112 PMID:14563492 PMID:14647439 PMID:14871405 PMID:15316927 PMID:15589375 PMID:16109301 PMID:16462769 PMID:16631525 PMID:16647178 PMID:16839318 PMID:16959797 PMID:17173083 PMID:17204476 PMID:17275847 PMID:17420286 PMID:17464175 PMID:17541025 PMID:17979934 PMID:18206168 PMID:18215737 PMID:18357586 PMID:18550526 PMID:18845130 PMID:19080378 PMID:19136476 PMID:19190261 PMID:19520142 PMID:20016031 PMID:20638379 PMID:20961405 PMID:21525764 PMID:22859313 PMID:23272707 PMID:23942037 PMID:24095726 PMID:25268984 PMID:25449124 PMID:25824035 PMID:26747958 PMID:27777014 PMID:27815112 PMID:27830717 PMID:29086419 PMID:29749404 PMID:29797346 PMID:30040983 PMID:31054940 PMID:31518892 PMID:32671443 PMID:33434570 PMID:35691465 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases response to substance |
ISO |
HMOX2 protein results in decreased susceptibility to Hemin |
CTD |
PMID:15589375 PMID:16459095 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Hemin results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA |
CTD |
PMID:12393473 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10349844 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il18 |
interleukin 18 |
multiple interactions decreases response to substance |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein]; Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein] |
CTD |
PMID:35691465 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of IL6 mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] |
CTD |
PMID:29749404 PMID:35691465 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Fructose results in increased expression of INS protein] |
CTD |
PMID:25268984 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions |
EXP |
Hemin results in decreased expression of and results in decreased activity of IREB2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
Hemin results in decreased expression of IVL mRNA |
CTD |
PMID:20006635 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
ISO EXP |
[Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Hemin promotes the reaction [Paraquat results in increased phosphorylation of JUN protein] Hemin results in decreased expression of JUN mRNA |
CTD |
PMID:12393473 PMID:19080378 PMID:20016031 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression |
ISO |
Hemin results in decreased expression of KEAP1 protein |
CTD |
PMID:27777014 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Magi1 |
membrane associated guanylate kinase, WW and PDZ domain containing 1 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 mRNA; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Hemin results in increased phosphorylation of MAPK1 protein diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16959797 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein] |
CTD |
PMID:18215737 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16959797 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Hemin promotes the reaction [Paraquat results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19080378 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions decreases expression |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA] Hemin results in decreased expression of MAPK9 mRNA |
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]] |
CTD |
PMID:27830717 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Gallic Acid results in increased activity of MGST1 protein] |
CTD |
PMID:19111564 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir126a |
microRNA 126a |
decreases expression |
ISO |
Hemin results in decreased expression of MIR126 mRNA |
CTD |
PMID:28733890 |
|
NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180
|
|
G |
Mir451a |
microRNA 451a |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of MIR451A mRNA hydroquinone affects the reaction [Hemin results in increased expression of MIR451A mRNA] |
CTD |
PMID:28733890 |
|
NCBI chr10:62,961,520...62,961,591
Ensembl chr10:62,961,520...62,961,591
|
|
G |
Mir486 |
microRNA 486 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of MIR486-1 mRNA [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of MIR486-1 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Hemin results in increased expression of MMP1 protein |
CTD |
PMID:19136476 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:17979934 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA |
CTD |
PMID:12393473 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA |
CTD |
PMID:12393473 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NFE2 mRNA catechol promotes the reaction [Hemin results in increased expression of NFE2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of NFE2 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of NFE2 mRNA] |
CTD |
PMID:21414390 PMID:28552822 |
|
NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression increases expression affects localization |
ISO EXP |
[Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of and affects the localization of NFE2L2 protein; diacetyldichlorofluorescein inhibits the reaction [Hemin affects the localization of NFE2L2 protein]; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; Hemin results in increased expression of and affects the localization of NFE2L2 protein; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA] Hemin results in decreased expression of NFE2L2 protein [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Hemin] affects the localization of NFE2L2 protein; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] |
CTD |
PMID:10473555 PMID:16959797 PMID:21464371 PMID:21525764 PMID:22859313 PMID:23272707 PMID:25824035 PMID:26747958 PMID:27777014 PMID:31054940 PMID:33434570 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]; Hemin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Hemin promotes the reaction [3-hydroxyflavone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein] |
CTD |
PMID:14563492 PMID:15316927 PMID:26747958 PMID:27815112 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[Nitroglycerin co-treated with Hemin] results in increased expression of NOS3 mRNA |
CTD |
PMID:17541025 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NQO1 mRNA; Hemin results in increased expression of NQO1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 protein; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] |
CTD |
PMID:21464371 PMID:31054940 PMID:33434570 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of NRF1 protein] |
CTD |
PMID:30040983 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein] |
CTD |
PMID:27231347 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases expression |
EXP |
Hemin results in decreased expression of PDE5A protein |
CTD |
PMID:16839318 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein |
CTD |
PMID:20961405 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of PDGFRB mRNA |
CTD |
PMID:32198055 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases activity |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Dimethyl Sulfoxide promotes the reaction [Hemin results in decreased activity of POR protein]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin promotes the reaction [Dimethyl Sulfoxide results in decreased activity of POR protein] |
CTD |
PMID:11368792 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of PPARGC1A protein] |
CTD |
PMID:30040983 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
increases response to substance |
ISO |
PTGER2 gene mutant form results in increased susceptibility to Hemin |
CTD |
PMID:25451967 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAP1A protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr13:42,637,513...42,703,024
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] Hemin results in decreased expression of RELA mRNA |
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions affects response to substance increases expression |
ISO |
[SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form Hemin results in increased expression of SESN2 protein [Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; Acetylcysteine inhibits the reaction [Hemin results in increased expression of SESN2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] |
CTD |
PMID:31054940 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]]; Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19190261 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Hemin promotes the reaction [Acetaminophen results in increased expression of SOD2 protein] |
CTD |
PMID:12051994 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Syn1 |
synapsin I |
multiple interactions |
ISO |
Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of SYN1 protein] |
CTD |
PMID:36096218 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Tfap2c |
transcription factor AP-2 gamma |
decreases expression |
EXP |
Hemin results in decreased expression of TFAP2C mRNA |
CTD |
PMID:20016031 |
|
NCBI chr 3:161,315,114...161,322,998
Ensembl chr 3:161,315,031...161,322,995
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
EXP ISO |
Hemin results in decreased expression of TFRC protein [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; hydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of TFRC mRNA] Hemin results in decreased expression of TFRC mRNA; Hemin results in decreased expression of TFRC protein |
CTD |
PMID:12393473 PMID:16568477 PMID:16760464 PMID:21414390 PMID:25576684 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[Hemin co-treated with Tretinoin] affects the localization of TGM2 protein |
CTD |
PMID:15556610 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of TNF mRNA; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased expression of TNF]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:17173083 PMID:19150641 PMID:26747958 PMID:27815112 PMID:29269057 PMID:35691465 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
EXP |
Hemin inhibits the reaction [Nitroglycerin results in decreased phosphorylation of VASP protein] |
CTD |
PMID:17541025 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases splicing |
ISO |
Hemin results in increased splicing of XBP1 mRNA |
CTD |
PMID:35341795 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Zfp36 |
zinc finger protein 36 |
multiple interactions increases expression |
ISO |
zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of ZFP36 mRNA] |
CTD |
PMID:24095726 |
|
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]] zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] |
CTD |
PMID:20052772 PMID:20861358 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:20523338 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [olprinone results in increased activity of AKT1 protein] |
CTD |
PMID:19387321 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
affects abundance |
ISO |
ALAD gene SNP affects the abundance of zinc protoporphyrin |
CTD |
PMID:25963508 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin results in increased expression of HMOX1 protein] zinc protoporphyrin inhibits the reaction [ALB protein results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [ALB protein results in increased expression of TIMP1 protein] |
CTD |
PMID:19376148 PMID:21163135 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ALMS1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 4:118,125,581...118,226,005
Ensembl chr 4:118,125,607...118,226,005
|
|
G |
Ap2a1 |
adaptor related protein complex 2 subunit alpha 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of AP2A1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 1:95,384,306...95,414,170
Ensembl chr 1:95,384,309...95,414,147
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of AP3D1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ASF1A mRNA |
CTD |
PMID:22839698 |
|
NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of BAX protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]] zinc protoporphyrin inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:22763982 PMID:27523796 PMID:27815112 PMID:32621855 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]] |
CTD |
PMID:22763982 PMID:27523796 PMID:32621855 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
EXP ISO |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of BCL2L1 protein] zinc protoporphyrin results in increased expression of BCL2L1 protein |
CTD |
PMID:20357190 PMID:27829220 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
zinc protoporphyrin results in increased expression of BCL2L11 protein |
CTD |
PMID:27829220 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BIRC3 protein] |
CTD |
PMID:18508827 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [monophosphoryl lipid A results in increased expression of CALCA mRNA] |
CTD |
PMID:11738242 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cand1 |
cullin-associated and neddylation-dissociated 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CAND1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:54,681,114...54,719,002
Ensembl chr 7:54,680,900...54,718,993
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of CASP1 protein]] |
CTD |
PMID:36858639 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases activity |
ISO EXP |
zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [T-2 Toxin results in increased activity of CASP3 protein] zinc protoporphyrin results in increased cleavage of CASP3 protein zinc protoporphyrin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; zinc protoporphyrin promotes the reaction [quinocetone results in increased activity of CASP3 protein] zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]]; zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein] zinc protoporphyrin results in decreased activity of CASP3 protein |
CTD |
PMID:16051694 PMID:17928392 PMID:20357190 PMID:21295052 PMID:22763982 PMID:25003661 PMID:26747958 PMID:27375190 PMID:27815112 PMID:28025122 PMID:29432840 PMID:30261164 PMID:32621855 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP8 protein] |
CTD |
PMID:16051694 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP9 protein]]; zinc protoporphyrin promotes the reaction [quinocetone results in increased activity of CASP9 protein] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein]]; zinc protoporphyrin promotes the reaction [T-2 Toxin results in increased activity of CASP9 protein] |
CTD |
PMID:27375190 PMID:29432840 PMID:30261164 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of CAT protein]] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]] |
CTD |
PMID:32621855 PMID:35691465 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of CCDC6 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of CCL2 protein]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of CCL2 mRNA] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]] |
CTD |
PMID:20357190 PMID:23892052 PMID:35691465 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CCR7 mRNA] |
CTD |
PMID:33049506 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA] |
CTD |
PMID:33049506 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 mRNA] |
CTD |
PMID:33049506 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd83 |
CD83 molecule |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 mRNA] |
CTD |
PMID:33049506 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 mRNA] |
CTD |
PMID:33049506 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdk13 |
cyclin-dependent kinase 13 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CDK13 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr17:47,251,145...47,344,675
Ensembl chr17:47,251,163...47,341,721
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of and affects the localization of CDKN1A protein] |
CTD |
PMID:18508827 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chd7 |
chromodomain helicase DNA binding protein 7 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CHD7 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 5:21,812,007...21,995,358
Ensembl chr 5:21,812,070...21,995,358
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CMBL mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
zinc protoporphyrin results in increased expression of CXCL1 mRNA |
CTD |
PMID:25780291 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]] |
CTD |
PMID:20861358 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
EXP |
zinc protoporphyrin results in increased expression of CXCL2 mRNA |
CTD |
PMID:25780291 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP1A1 protein |
CTD |
PMID:26747958 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP1A2 protein |
CTD |
PMID:26747958 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2B1 protein |
CTD |
PMID:26747958 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2E1 mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2E1 protein; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] zinc protoporphyrin inhibits the reaction [Quercetin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [Ethanol results in increased activity of CYP2E1 protein]] |
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dcun1d1 |
defective in cullin neddylation 1 domain containing 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of DCUN1D1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:118,721,275...118,772,606
Ensembl chr 2:118,721,822...118,772,602
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhx29 |
DExH-box helicase 29 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of DHX29 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:44,560,653...44,611,450
Ensembl chr 2:44,560,714...44,611,445
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [andrographolide results in increased expression of DUSP10 mRNA]; zinc protoporphyrin inhibits the reaction [andrographolide results in increased expression of DUSP10 protein] |
CTD |
PMID:29165873 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eml4 |
EMAP like 4 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of EML4 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased expression of PTGS2 protein]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased secretion of Dinoprostone]] |
CTD |
PMID:26385185 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP8 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased cleavage of CASP3 protein] |
CTD |
PMID:16051694 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxw12 |
F-box and WD repeat domain containing 12 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FBXW12 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 8:109,782,315...109,802,086
Ensembl chr 8:109,786,815...109,801,813
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FGFR1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]] |
CTD |
PMID:25371888 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
zinc protoporphyrin results in increased expression of FOS mRNA |
CTD |
PMID:10381381 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of FUT4 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Ammonia results in decreased activity of GLUL protein]]; zinc protoporphyrin inhibits the reaction [Resveratrol results in increased activity of GLUL protein] |
CTD |
PMID:26318273 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpr132 |
G protein-coupled receptor 132 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of GPR132 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:131,924,061...131,943,327
Ensembl chr 6:131,924,160...131,942,168
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of GPX1 protein] |
CTD |
PMID:36696656 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of GPX4 protein] |
CTD |
PMID:36696656 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of GSDMD protein]] |
CTD |
PMID:36858639 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Haus2 |
HAUS augmin like complex subunit 2 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of HAUS2 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 3:107,553,146...107,565,982
Ensembl chr 3:107,553,161...107,565,157
|
|
G |
Hfe |
homeostatic iron regulator |
affects abundance |
ISO |
HFE gene polymorphism affects the abundance of zinc protoporphyrin |
CTD |
PMID:25963508 |
|
NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [HIF1A protein results in increased activity of SOD2 protein] |
CTD |
PMID:17066447 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP ISO |
zinc protoporphyrin promotes the reaction [lead acetate results in increased expression of HMGB1 mRNA] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased expression of HMGB1 protein]] |
CTD |
PMID:29447957 PMID:30261164 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression increases expression affects expression decreases activity |
ISO EXP |
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in increased susceptibility to 2-butenal; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in increased susceptibility to Arsenic Trioxide; [zinc protoporphyrin results in decreased activity of HMOX1] which results in decreased susceptibility to peoniflorin; zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Ethanol results in decreased abundance of Glutathione]]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Ethanol results in increased abundance of Malondialdehyde]]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in decreased susceptibility to Ethanol]; zinc protoporphyrin inhibits the reaction [ALB protein results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Cilostazol results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Cilostazol results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased activity of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]; zinc protoporphyrin results in decreased expression of and results in decreased activity of HMOX1 protein; zinc protoporphyrin results in increased expression of and results in decreased activity of HMOX1 protein zinc protoporphyrin results in decreased expression of HMOX1 mRNA; zinc protoporphyrin results in decreased expression of HMOX1 protein zinc protoporphyrin results in increased expression of HMOX1 protein zinc protoporphyrin affects the expression of HMOX1 mRNA; zinc protoporphyrin affects the expression of HMOX1 protein zinc protoporphyrin results in decreased activity of HMOX1; zinc protoporphyrin results in decreased activity of HMOX1 protein zinc protoporphyrin results in increased expression of HMOX1 mRNA; zinc protoporphyrin results in increased expression of HMOX1 protein [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of HMOX1 mRNA; [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with zinc protoporphyrin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [Resveratrol results in increased abundance of Glutathione]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in decreased susceptibility to Resveratrol; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [lead acetate results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [olprinone results in increased activity of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [perflexane promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of and results in increased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Sildenafil Citrate results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Sildenafil Citrate results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of HMOX1 protein] [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; ALB protein inhibits the reaction [zinc protoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone] results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Cisplatin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of HMOX1 protein]] |
CTD |
PMID:7524564 PMID:12352873 PMID:14649057 PMID:15602829 PMID:16462769 PMID:17292349 PMID:17627722 PMID:17928392 PMID:18006204 PMID:18042465 PMID:18073186 PMID:18508827 PMID:19019021 PMID:19136476 PMID:19376148 PMID:19387321 PMID:19608869 PMID:20052772 PMID:20056245 PMID:20131233 PMID:20357190 PMID:20360627 PMID:20523338 PMID:21163135 PMID:21238556 PMID:21253390 PMID:21295052 PMID:21315065 PMID:21327864 PMID:21382476 PMID:21448202 PMID:21518603 PMID:21660147 PMID:21690482 PMID:21925249 PMID:22118543 PMID:22763982 PMID:22859313 PMID:22864849 PMID:23403272 PMID:23525258 PMID:23691207 PMID:23704825 PMID:24003391 PMID:24810525 PMID:25780291 PMID:25824035 PMID:26747958 PMID:27523796 PMID:27815112 PMID:27829220 PMID:27830717 PMID:29447957 PMID:31356851 PMID:32621855 PMID:33049506 PMID:34029560 PMID:35691465 PMID:36696656 PMID:36858639 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases activity decreases expression |
ISO EXP |
zinc protoporphyrin results in decreased activity of HMOX2 protein zinc protoporphyrin results in decreased expression of HMOX2 protein |
CTD |
PMID:21448202 PMID:25824035 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hp1bp3 |
heterochromatin protein 1, binding protein 3 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of HP1BP3 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 5:150,435,781...150,463,004
Ensembl chr 5:150,433,740...150,463,000
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of HSD11B1 mRNA]] |
CTD |
PMID:27523796 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of ICAM1 mRNA] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA] |
CTD |
PMID:19608869 PMID:23892052 PMID:33049506 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]] |
CTD |
PMID:20861358 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
EXP |
zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein] zinc protoporphyrin results in increased expression of IFNG mRNA |
CTD |
PMID:21295052 PMID:25780291 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of IL10 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of IL10 protein]; zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of IL10 protein]] |
CTD |
PMID:20056245 PMID:20360627 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
zinc protoporphyrin promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]] |
CTD |
PMID:33049506 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL18 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein] |
CTD |
PMID:18215737 PMID:36858639 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
zinc protoporphyrin inhibits the reaction [Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL1B protein]] zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]] zinc protoporphyrin results in increased expression of IL1B mRNA zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of IL1B mRNA] |
CTD |
PMID:20131233 PMID:21295052 PMID:23892052 PMID:25780291 PMID:27523796 PMID:30261164 PMID:35691465 PMID:36858639 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL23A mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL23A protein]] |
CTD |
PMID:33049506 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]] zinc protoporphyrin results in increased expression of IL6 mRNA zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; zinc protoporphyrin inhibits the reaction [manganese chloride promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]] |
CTD |
PMID:19608869 PMID:20131233 PMID:21963524 PMID:25780291 PMID:27523796 PMID:30261164 PMID:33049506 PMID:35691465 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
decreases expression |
EXP |
zinc protoporphyrin results in decreased expression of INPP5D protein |
CTD |
PMID:25780291 |
|
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
EXP |
zinc protoporphyrin promotes the reaction [IRAK1 protein binds to MYD88 protein] |
CTD |
PMID:25780291 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
decreases expression |
EXP |
zinc protoporphyrin results in decreased expression of IRAK3 protein |
CTD |
PMID:25780291 |
|
NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression |
ISO |
zinc protoporphyrin results in increased expression of ITGAM protein |
CTD |
PMID:22118543 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased expression of JUN protein] zinc protoporphyrin results in increased expression of JUN protein |
CTD |
PMID:27829220 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnab1 |
potassium voltage-gated channel subfamily A regulatory beta subunit 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCNAB1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:149,137,025...149,603,540
Ensembl chr 2:149,137,041...149,603,534
|
|
G |
Kctd20 |
potassium channel tetramerization domain containing 20 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCTD20 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr20:7,015,828...7,032,766
Ensembl chr20:7,015,833...7,032,761
|
|
G |
Kidins220 |
kinase D-interacting substrate 220 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of KIDINS220 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:41,618,207...41,706,990
Ensembl chr 6:41,618,294...41,703,256
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KITLG mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KRAS mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Larp1b |
La ribonucleoprotein 1B |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LARP1B mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:123,936,057...123,969,254
Ensembl chr 2:123,935,983...123,968,896
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of LDHA protein]] |
CTD |
PMID:36858639 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lnx1 |
ligand of numb-protein X 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LNX1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr14:33,514,429...33,617,086
Ensembl chr14:33,514,436...33,617,086
|
|
G |
Lyrm7 |
LYR motif containing 7 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LYRM7 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr10:38,964,299...38,983,628
Ensembl chr10:38,964,311...38,983,601
|
|
G |
Macf1 |
microtubule-actin crosslinking factor 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MACF1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]] zinc protoporphyrin results in increased phosphorylation of MAPK1 protein zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; zinc protoporphyrin promotes the reaction [lipoteichoic acid results in increased phosphorylation of MAPK1 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19376148 PMID:20523338 PMID:27523796 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]] zinc protoporphyrin results in increased phosphorylation of MAPK3 protein zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin promotes the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19376148 PMID:20523338 PMID:27523796 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mark2 |
microtubule affinity regulating kinase 2 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MARK2 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein] |
CTD |
PMID:27830717 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mllt3 |
MLLT3, super elongation complex subunit |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MLLT3 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 5:102,259,075...102,515,447
Ensembl chr 5:102,260,011...102,515,361
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
affects expression multiple interactions |
EXP ISO |
zinc protoporphyrin affects the expression of MMP2 zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 protein] |
CTD |
PMID:23704825 PMID:30076913 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased expression of MMP9 protein] zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 protein] |
CTD |
PMID:27829220 PMID:30076913 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of MPO protein]]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased activity of MPO protein]; zinc protoporphyrin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 PMID:20360627 PMID:23892052 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
zinc protoporphyrin promotes the reaction [IRAK1 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TLR2 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TLR4 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TRAF6 protein binds to MYD88 protein] |
CTD |
PMID:25780291 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]] |
CTD |
PMID:19608869 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects expression |
EXP |
zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] zinc protoporphyrin affects the expression of NFE2L2 mRNA; zinc protoporphyrin affects the expression of NFE2L2 protein |
CTD |
PMID:23704825 PMID:25824035 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]] |
CTD |
PMID:21925249 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [cilostazol results in increased expression of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of NFKBIA protein] zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]] |
CTD |
PMID:20131233 PMID:21925249 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
[Sildenafil Citrate co-treated with zinc protoporphyrin] results in increased expression of NOS1 mRNA |
CTD |
PMID:17627722 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
[zinc protoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of NOS2 mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of NOS2 protein; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of NOS2 mRNA]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [Ethanol results in increased expression of NOS2 mRNA]]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein] |
CTD |
PMID:19376148 PMID:20357190 PMID:21925249 PMID:26460608 PMID:26747958 PMID:32621855 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pde4dip |
phosphodiesterase 4D interacting protein |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PDE4DIP mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379
|
|
G |
Pgf |
placental growth factor |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PGF mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:104,816,102...104,826,685
Ensembl chr 6:104,816,104...104,826,685
|
|
G |
Polr3k |
RNA polymerase III subunit K |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of POLR3K mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 3:168,982,846...168,987,043
Ensembl chr 3:168,982,812...168,987,040
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [cilostazol results in increased activity of PPARG protein]; zinc protoporphyrin inhibits the reaction [rosiglitazone results in increased activity of PPARG protein] |
CTD |
PMID:21660147 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppil1 |
peptidylprolyl isomerase like 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of PPIL1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr20:7,302,292...7,322,349
Ensembl chr20:7,302,621...7,322,354
|
|
G |
Prdx2 |
peroxiredoxin 2 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PRDX2 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prr11 |
proline rich 11 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PRR11 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased expression of PTGS2 protein]]; zinc protoporphyrin promotes the reaction [Arsenic Trioxide results in increased expression of PTGS2] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:23649692 PMID:24003391 PMID:26385185 PMID:30261164 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn12 |
protein tyrosine phosphatase, non-receptor type 12 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of PTPN12 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 4:14,020,997...14,092,931
Ensembl chr 4:14,021,052...14,092,927
|
|
G |
Ptpro |
protein tyrosine phosphatase, receptor type, O |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PTPRO mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 4:170,164,071...170,374,790
Ensembl chr 4:170,164,431...170,374,771
|
|
G |
Rap2c |
RAP2C, member of RAS oncogene family |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of RAP2C mRNA |
CTD |
PMID:22839698 |
|
NCBI chr X:130,504,554...130,517,671
Ensembl chr X:130,504,698...130,518,328
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased expression of RELA mRNA]]; zinc protoporphyrin promotes the reaction [quinocetone results in increased expression of RELA mRNA] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of RELA protein] zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]] |
CTD |
PMID:19608869 PMID:20131233 PMID:20357190 PMID:21925249 PMID:27375190 PMID:27523796 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgcc |
regulator of cell cycle |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of RGCC mRNA |
CTD |
PMID:22839698 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Scaf11 |
SR-related CTD-associated factor 11 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SCAF11 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:127,571,678...127,624,089
Ensembl chr 7:127,574,463...127,624,101
|
|
G |
Scamp1 |
secretory carrier membrane protein 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SCAMP1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:25,433,958...25,516,734
Ensembl chr 2:25,433,959...25,516,673
|
|
G |
Sec23b |
Sec23 homolog B, COPII coat complex component |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SEC23B mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 3:131,939,011...131,981,489
Ensembl chr 3:131,939,337...131,981,489
|
|
G |
Sel1l |
SEL1L adaptor subunit of SYVN1 ubiquitin ligase |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SEL1L mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:110,735,450...110,779,695
Ensembl chr 6:110,735,450...110,779,648
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Fenofibrate results in increased expression of SIRT1 protein] |
CTD |
PMID:34520103 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SLC22A3 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc35e1 |
solute carrier family 35, member E1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SLC35E1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr16:17,350,938...17,364,185
Ensembl chr16:17,350,988...17,363,268
|
|
G |
Smcr8 |
SMCR8-C9orf72 complex subunit |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SMCR8 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr10:45,457,962...45,465,101
Ensembl chr10:45,457,605...45,468,876
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SOD2 mRNA; zinc protoporphyrin inhibits the reaction [HIF1A protein results in increased activity of SOD2 protein] |
CTD |
PMID:17066447 PMID:22839698 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sptbn1 |
spectrin, beta, non-erythrocytic 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SPTBN1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]] |
CTD |
PMID:19608869 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Ssbp3 |
single stranded DNA binding protein 3 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SSBP3 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 5:121,691,370...121,828,035
Ensembl chr 5:121,691,393...121,827,992
|
|
G |
St3gal1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ST3GAL1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [Ozone results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:19061877 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP ISO |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]] zinc protoporphyrin inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:24095726 PMID:24810525 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
affects expression decreases secretion increases expression |
EXP |
zinc protoporphyrin affects the expression of TGFB1 zinc protoporphyrin results in decreased secretion of TGFB1 protein zinc protoporphyrin results in increased expression of TGFB1 protein |
CTD |
PMID:21163135 PMID:23525258 PMID:23704825 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
affects expression multiple interactions |
EXP ISO |
zinc protoporphyrin affects the expression of TIMP1 zinc protoporphyrin promotes the reaction [ALB protein results in increased expression of TIMP1 protein] |
CTD |
PMID:21163135 PMID:23704825 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
EXP |
zinc protoporphyrin promotes the reaction [TLR2 protein binds to MYD88 protein] |
CTD |
PMID:25780291 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
zinc protoporphyrin promotes the reaction [TLR4 protein binds to MYD88 protein] |
CTD |
PMID:25780291 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [cilostazol results in decreased susceptibility to TNF protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of TNF mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of TNF protein; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [naringenin results in decreased activity of TNF protein]; zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of TNF protein]]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]]; zinc protoporphyrin inhibits the reaction [manganese chloride promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] |
CTD |
PMID:19608869 PMID:20052772 PMID:20131233 PMID:20360627 PMID:21660147 PMID:21925249 PMID:21963524 PMID:22709785 PMID:24095726 PMID:26747958 PMID:30261164 PMID:32621855 PMID:33049506 PMID:35691465 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]] |
CTD |
PMID:19608869 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnrc6a |
trinucleotide repeat containing adaptor 6A |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of TNRC6A mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 1:177,561,898...177,715,669
Ensembl chr 1:177,646,030...177,715,660
|
|
G |
Tollip |
toll interacting protein |
decreases expression |
EXP |
zinc protoporphyrin results in decreased expression of TOLLIP protein |
CTD |
PMID:25780291 |
|
NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO EXP |
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of TP53 protein] zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]] |
CTD |
PMID:18042465 PMID:20357190 PMID:22763982 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
EXP |
zinc protoporphyrin promotes the reaction [TRAF6 protein binds to MYD88 protein] |
CTD |
PMID:25780291 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Ubxn2a |
UBX domain protein 2A |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of UBXN2A mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:27,884,364...27,912,767
Ensembl chr 6:27,884,680...27,912,649 Ensembl chr20:27,884,680...27,912,649
|
|
G |
Usp13 |
ubiquitin specific peptidase 13 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of USP13 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:115,576,912...115,689,153
Ensembl chr 2:115,577,091...115,686,222
|
|
G |
Usp34 |
ubiquitin specific peptidase 34 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of USP34 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr14:97,285,799...97,476,376
Ensembl chr14:97,286,018...97,476,376
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of VCAM1 mRNA] |
CTD |
PMID:19608869 PMID:23892052 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vdr |
vitamin D receptor |
affects abundance |
ISO |
VDR gene polymorphism affects the abundance of zinc protoporphyrin |
CTD |
PMID:25963508 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vps33a |
VPS33A core subunit of CORVET and HOPS complexes |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of VPS33A mRNA |
CTD |
PMID:22839698 |
|
NCBI chr12:33,024,596...33,051,399
Ensembl chr12:33,024,650...33,051,393
|
|
G |
Wsb2 |
WD repeat and SOCS box-containing 2 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of WSB2 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr12:39,217,645...39,238,634
Ensembl chr12:39,217,648...39,238,640
|
|
G |
Zfp36 |
zinc finger protein 36 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Nicotine results in increased expression of ZFP36 mRNA] |
CTD |
PMID:24095726 |
|
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
|
|
G |
Zfp827 |
zinc finger protein 827 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ZNF827 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr19:28,720,568...28,887,381
Ensembl chr19:28,721,021...28,887,191
|
|
G |
Zfyve16 |
zinc finger FYVE-type containing 16 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ZFYVE16 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:23,713,018...23,757,576
Ensembl chr 2:23,713,766...23,756,990
|
|